Alto Neuroscience (ANRO) Other Non-Current Assets (2023 - 2026)
Alto Neuroscience (ANRO) posted Other Non-Current Assets of $500000.0 for Q1 2026, up 47.93% sequentially from $338000.0 in Q4 2025, and down 12.13% YoY from $569000.0 in Q1 2025.
Powered by 
Analysis
Alto Neuroscience (ANRO) Other Non-Current Assets (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Other Non-Current Assets for 3 years, with the latest figure at $500000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 12.13% year-over-year to $500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $500000.0 (down 12.13% YoY) and the FY2025 annual result came in at $338000.0, up 8350.0% from the prior year.
- Other Non-Current Assets climbed to $500000.0 in Q1 2026 per ANRO's latest filing, from $338000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $570000.0 in Q3 2025 and troughed at $4000.0 in Q2 2024.
- A 3-year average of $338111.1 and a median of $500000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets jumped 12400.0% in 2025, then dropped 12.13% in 2026.
- Over 3 years, Other Non-Current Assets stood at $4000.0 in 2024, then surged by 8350.0% to $338000.0 in 2025, then soared by 47.93% to $500000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $500000.0, $338000.0, and $570000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | 500,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 570,000.00 |
| Jun 30, 2025 | 570,000.00 |
| Mar 31, 2025 | 569,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Dec 31, 2023 | 131,000.00 |